Most CanPath study participants had infection-acquired antibodies but few suspected COVID-19

Dr. Victoria Kirsh presented at a CanPath webinar this week to present results from the SUPPORT-Canada study, funded by the federal COVID-19 Immunity Task Force (CITF). Data and blood spot samples were used from 22,300 participants from Atlantic PATH, CARTaGENE, the Ontario Health Study, Manitoba Tomorrow Project, Alberta’s Tomorrow Project, and BC Generations. Key findings include: Read more about Most CanPath study participants had infection-acquired antibodies but few suspected COVID-19[…]

CanPath Webinar: COVID-19 Findings

CanPath Webinar: Real-World Insights on COVID-19 Vaccine Effectiveness and Infection Risk Factors from CanPath’s SUPPORT-Canada Study May 30th, 12-1pmEST/1-2pmAST Register: https://canpath.ca/2023/04/hybrid-event-covid-19-vaccine-effectiveness-support-canada-study/ Join us for an in-depth analysis of COVID-19 vaccine effectiveness based on real-world data from the SUrveying Prospective Population cOhorts for COVID-19 pRevalence and ouTcomes in Canada’ (SUPPORT-Canada) study. Led by Victoria Kirsh, this webinar will Read more about CanPath Webinar: COVID-19 Findings[…]

The Ontario Public Health Convention (TOPHC)

Dr. Ellen Sweeney (Research Director, Atlantic PATH) and Dr. Victoria Kirsh (Scientific Associate, Ontario Health Study) were pleased to attend the Ontario Public Health Convention (TOPHC) on behalf of CanPath. Dr. Sweeney presented on CanPath’s resources for research on chronic disease and cancer and Dr. Kirsh presented on risk factors for COVID-19 infection among CanPath Read more about The Ontario Public Health Convention (TOPHC)[…]

Congratulations to Dr. Robin Urquhart and the CanPath team across the country!

Funded by the Canadian Cancer Society Data Transformation Grant, this work will connect cancer registry and administrative health data with CanPath data creating a unified resource for cancer research in Canada. https://bit.ly/3OojlZ2 Urquhart R, Awadalla P, Bhatti P, Dummer T, Gravel S, Vena J, Alvi R, Broet P, Kendell C, Kirsh V, Lettre G, Skead Read more about Congratulations to Dr. Robin Urquhart and the CanPath team across the country![…]

CanPath to Study the Impact and Immune Response to COVID-19 Infection and Vaccination

The Government of Canada is investing $1.9m through the COVID-19 Immunity Task Force (CITF) to fund an extension of CanPath’s COVID-19 Antibody Study over a longer period of time, allowing for additional collection of blood samples and questionnaires. The CanPath COVID-19 Antibody Study is implemented in collaboration with CanPath’s regional cohorts, including Atlantic PATH, CARTaGENE (Quebec), Read more about CanPath to Study the Impact and Immune Response to COVID-19 Infection and Vaccination[…]